SUMMARY Postprandial pancreatic secretion results from the interaction of neural and hormonal factors but their contribution to the net postprandial secretion is unknown. Recent description of highly specific and potent cholecystokinin (CCK) receptor antagonists allows the determination of the physiological role of CCK in the postprandial pancreatic secretion. In six dogs with chronic pancreatic fistulae, the blockade of CCK receptors by non-peptidal agent (L-364 718) caused little change in basal pancreatic secretion, but decreased significantly (p<005) by about 60% the pancreatic protein response to meat feeding and virtually abolished the pancreatic responses to CCK-8 and bombesin. The pancreatic protein responses to pentagastrin, reaching about 37% of CCK maximum, was also significantly reduced but this effect was less pronounced than that observed in tests with CCK-8 or bombesin stimulation. In contrast, cholinergically stimulated pancreatic secretion, reaching about 40% of CCK maximum, was unaffected by L-364 718. Cholecystokinin antagonism also failed to affect the postprandial and bombesin induced increments in plasma CCK and gastrin concentrations, but significantly reduced the PP responses to CCK-8 bombesin and meat feeding possibly as a result of the removal ofthe CCK mediated release of PP. We conclude that CCK plays a crucial role in the mediation of the postprandial and bombesin induced pancreatic secretion and in the PP release.
mediators in the postprandial pancreatic secretion. I The assessment of the hormonal contribution has been possible because of a recent description of I highly specific and potent peptidal and non-peptidal I CCK receptor antagonists""'2 which allow the pancreatic responses to be measured in the absence I of the effect of CCK.
This study was undertaken to clarify the contribution of CCK and gastrin in the postprandial pan-I creatic secretion as well as in the pancreatic responses to exogenous hormonal peptides such as CCK-8, gastrin, and bombesin by using one of the most potent antagonists (L-364 718) of CCK receptors1'2 in conscious dogs with chronic gastric and pancreatic fistulae. 110
Methods

DOGS
Studies in vivo were carried out on six mongrel dogs, weighing 18-20 kg, and prepared surgically with gastric (GF) and pancreatic fistulae (PF) as described before.8 ' The studies reported here started about five months after surgery. Food was withheld for at least 18 hours before each test. Throughout all tests, except those with feeding, the GF was left open to allow for draining of gastric juice to the outside to prevent gastric acid from entering the duodenum and releasing endogenous hormones.
Secretions from the GF and PF were collected continuously and divided into 15 minute aliquots. The volume was recorded and acid concentration in the gastric juice and bicarbonate and protein concentrations in the pancreatic juice were measured in each sample and presented in 15 or 30 minute outputs.
Several tests were carried out in each animal. In tests with basal secretion, two hour collections were first obtained and then CCK receptor antagonist, L-364 718 (gift of Dr P S Anderson, Merck Sharp and Dohme Labs, West Point, PA) was injected intravenously in gradually increasing doses (3-5-240 jig/ kg), each dose being given separately at a 30 minute interval and then increased by the factor of four. L-364 718 is 3S-(-)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1, 4-benzodiazepine-3ryl)-1H-indole-2-carboxamide ( Fig. 1.) .
In tests with meal induced secretion, each dog was offered 500 g of cooked homogenised ground beef for 15 minutes and this was usually completely consumed. Gastric and pancreatic collections were made for 60 minutes before, during, and 210 minutes after the feeding. When the postprandial secretory rate reached a well sustained plateau, L-364 718 was injected intravenously as a single bolus dose (240 jg/ kg) and then the secretion was examined for subsequent 150 minutes. In tests with exogenous hormonal stimulation, synthetic CCK octapeptide (CCK-8) Plasma CCK and gastrin concentration showed a marked rise after feeding and L-364 718 did not affect significantly these levels ( Table 2 ). Pancreatic protein also showed a marked increment that was well sustained throughout the control postprandial period. L-364 718 caused a marked reduction in the PP increment by about 70% throughout the postprandial period.
Discussion
This study provides an evidence that CCK receptors of the acinar cells play an important role in the stimulation of pancreatic protein secretion in response to ordinary meat feeding, gastrin, and bombesin but not in the basal secretion and after cholinergic stimulation.
Previous studies using proglumide, that was originally designed by Rovati et all' as gastrin receptor antagonist for the treatment of peptic ulcer, showed that this agent administered in conscious dogs in massive dose (300 mg/kg/h) was also an effective inhibitor of the pancreatic responses to CCK-8 and duodenal perfusion with amino acids and fat but not bethanechol.'6 The action of proglumide was specific for CCK but its widespread usefulness was limited because of its very low potency. A series of competitive non-peptide benzodiazepine antagonists of cholecystokinin were synthetised'2 recently and the most potent L-364 718, has been characterised as highly specific and long acting CCK antagonist in a variety of biological systems.'2 It was found to be effective after oral and parenteral administration and exhibited the duration of action of two to three hours after a single iv dose administration.'7 This CCK antagonist has been examined for biliary and pancreatic secretion in conscious dogs.'8 When given orally it was found to inhibit the postprandial biliary secretion but, unexpectedly, failed to affect the postprandial pancreatic secretion despite its ability to antagonise the stimulatory action of exogenous CCK on this secretion. '8 In this study we used L-364 718 by intravenous injections in a dose range several times lower than that used in previous report'8 and found to be highly effective in the inhibition of pancreatic secretion induced not only by caerulein but also by meat feeding and bombesin. The failure of L-364 718 to suppress the postprandial pancreatic secretion in previous report'8 probably reflected an insufficient absorption of the drug after its intragastric administration rather than the lack of the involvement of CCK in this secretion. Indeed, our results provide a strong support for the notion that the pancreatic secretion induced by feeding and bombesin is mediated mainly by endogenous CCK. As the pancreatic response to bombesin can be completely blocked by L-364 718 at a dose that also totally suppressed pancreatic response to CCK-8, it may be concluded that bombesin stimulation is predominantly mediated by endogenous CCK. The same dose of L-364 718 reduced the postprandial pancreatic secretion by about 60% suggesting that CCK is the major but not the only factor involved in the secretory stimulation. As cholinergically stimulated pancreatic secretion is resistant to the inhibitory action of CCK antagonist, it is likely that cholinergic vagovagal reflexes originating in the stomach and the gut'W22 are involved in the postprandial pancreatic secretion. Such cholinergic gastro-and enteropancreatic reflexes may augment the stimulatory effect of CCK and by themselves may contribute at least 50% to postprandial pancreatic secretion.11 -4 This has been supported by several observations that vagotomy2225 and atropine2223 reduced the secretory responses to meal stimuli only from the intact but not from denervated (autotransplanted) pancreas and that the pancreatic enzyme response to luminal stimulation had shorter latency compared with that to intraportal injection of CCK.2' Using specific radioimmunoassay to measure the postprandial plasma concentrations of CCK, we reported that CCK is released postprandially in sufficient amounts to drive the major portion of the postprandial pancreatic secretion.89 This study showing that CCK-antagonist eliminates about 60% of the postprandial protein secretion confirms and reinforces the key role of CCK in the gastrointestinal phase of pancreatic secretion. This does not exclude the contribution of other, particularly neural, mechanisms which seem to be activated mainly in the early postprandial period before the humoral mechanisms are fully activated.' 2 The crucial question raised by the use of CCK antagonists is whether these agents also interfere with the effects of gastrin on gastric acid and pancreatic secretion. Gastrin and CCK share a common COOH-terminal pentapeptide amide, therefore, CCK agonists and antagonists should affect in a similar fashion the secretory activity of oxyntic cells and the acinar cells. Our present study shows that, unlike CCK, pentagastrin is only a partial agonist of pancreatic protein secretion. According to our results, pentagastrin used in the dose producing maximal gastric acid secretion, stimulated the pancreatic protein in conscious dogs only to about 37% of the CCK maximum and this is similar to that achieved by gastrin (G-17) used at a dose of 250 pmoll kg/h.26 This indicates that pentagastrin, though a less potent stimulant than gastrin, mimics, at least in part, the effect of gastrin on the pancreatic secretion. The addition of CCK antagonist to pentagastrin infusion caused only partial inhibition of gastrin induced gastric acid and pancreatic protein secretion suggesting that pentagastrin induced gastropancreatic secretion is less sensitive to the action of our CCK receptor antagonist. This remains in agreement with previous observation'6 that proglumide, a prototype of CCK receptor antagonist, was an effective inhibitor of pentagastrin induced gastric acid secretion in dogs only when larger doses of this agent were used or when lower doses of pentagastrin were used for gastric acid stimulation. As in other systems L-364718 was found to be highly specific for CCK receptor having no effect on gastrin receptors," further studies with authentic G-17 and G-34 are needed to determine whether gastric acid and pancreatic protein responses to gastrin itself is sensitive to the inhibitory action of L-364 718. The fact that the spectrum of biological activity of pentagastrin is similar to gastrin suggests that L-364 718 shows somewhat higher anti-CCK than antigastrin activity and that it is, therefore, more suitable for the study of CCK than gastrin in pancreatic physiology. The reason for the discrepancy in the action of CCK agonists and antagonists on gastric and pancreatic secretion in vivo is not apparent from our study but it may be because of the existence of two populations of CCK/gastrin receptors -that is, CCK preferring receptors and gastrin preferring receptors. The former receptor$ would predominate in the acinar cells and exhibit high affinity for CCK and its selective antagonists, while the latter receptors would predominate in the oxyntic cells and exhibit high affinity to gastrin but lower affinity to CCK and its antagonists. An alternative explanation would be that in vivo gastrin and CCK not only activate the CCK/gastrin receptors but also cause the release of local inhibitor of pancreatic and gastric secretion, respectively. Partial support for this notion is provided by recent observation that CCK is more potent than gastrin in releasing somatostatin from the gastric endocrine cells.27 Perhaps a similar inhibitor is released by gastrin in the pancreas but we have no support for such speculation. 
